Targeting Myeloid-Derived Suppressor Cells via Dual-Antibody Fluorescent Nanodiamond Conjugate

Fluorescent nanodiamonds (FNDs) are carbon-based nanomaterials that emit bright, photostable fluorescence and exhibit a modifiable surface chemistry. Myeloid-derived suppressor cells (MDSCs) are an immunosuppressive cell population known to expand in cancer patients and contribute to worse patient o...

Full description

Saved in:
Bibliographic Details
Published in:Nanomaterials (Basel, Switzerland) Switzerland), 2024-09, Vol.14 (18), p.1509
Main Authors: Angell, Colin D, Lapurga, Gabriella, Sun, Steven H, Johnson, Courtney, Savardekar, Himanshu, Rampersaud, Isaac V, Fletcher, Charles, Albertson, David, Ren, Casey, Suarez-Kelly, Lorena P, Rampersaud, Arfaan A, Carson, 3rd, William E
Format: Article
Language:English
Subjects:
Alcohol
Antibodies
antibody conjugation
Cancer
CD11b antigen
Chemokines
Diamonds
Ethylenediaminetetraacetic acid
Flow cytometry
Fluorescence
fluorescent nanodiamonds
Immune system
Immunoglobulin G
Immunotherapy
Injection
Liver cancer
MDSC
Nanomaterials
Nanostructure
Nanotechnology
PD-L1 protein
Polyethylene glycol
Quantum dots
Suppressor cells
Surface chemistry
Tumors
Vacuum distillation
Viral antibodies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fluorescent nanodiamonds (FNDs) are carbon-based nanomaterials that emit bright, photostable fluorescence and exhibit a modifiable surface chemistry. Myeloid-derived suppressor cells (MDSCs) are an immunosuppressive cell population known to expand in cancer patients and contribute to worse patient outcomes. To target MDSC, glycidol-coated FND were conjugated with antibodies against the murine MDSC markers, CD11b and GR1 (dual-Ab FND). In vitro, dual-Ab FND uptake by murine MDSC was significantly higher than IgG-coated FND (94.7% vs. 69.0%, < 0.05). In vivo, intra-tumorally injected dual-Ab FND primarily localized to the tumor 2 and 24 h post-injection, as measured by in vivo fluorescence imaging and flow cytometry analysis of the spleen and tumor. Dual-Ab FND were preferentially taken up by intra-tumoral MDSC, representing 87.1% and 83.0% of FND+ cells in the tumor 2 and 24 h post-injection, respectively. Treatment of mice with anti-PD-L1 immunotherapy prior to intra-tumoral injection of dual-Ab FND did not significantly alter the uptake of FND by MDSC. These results demonstrate the ability of our novel dual-antibody conjugated FND to target MDSC and reveal a potential strategy for targeted delivery to other specific immune cell populations in future cancer research.
ISSN:2079-4991
2079-4991
DOI:10.3390/nano14181509